Cyproheptadine Hydrochloride and Ruxolitinib Phosphate

• Generic Name: cyproheptadine
• Dosage Forms: n.a.
• Other Brand Names:

  Periactin

Treatment of cold urticaria.

Symptomatic relief of perennial (nonseasonal) and seasonal (e.g., hay fever) allergic rhinitis.

Management of nonallergic (vasomotor) rhinitis.

Management of allergic conjunctivitis caused by foods or inhaled allergens.

Management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

Treatment of dermatographism.

Amelioration of allergic reactions to blood or plasma.

Adjunct to epinephrine and other standard measures for management of anaphylactic reactions after acute manifestations have been controlled.

Has been effective in some patients for the treatment of Cushing’s syndrome secondary to pituitary disorders; however, in most patients, other therapy (e.g., surgery, radiation therapy) is preferred.

Has been effective for the management of inhibited male or female orgasm (anorgasmy) induced by tricyclic antidepressants, MAO inhibitors, fluoxetine, or antipsychotic agents. However, consider the potential for interactions between these drugs and cyproheptadine. (See Interactions.)

Has been shown to stimulate appetite and weight gain in children and adults; however, few indications for clinical use. May be of some value in the treatment of anorexia nervosa; may be more effective in nonbulimic patients than in those who are bulimic.

Reportedly has been effective in some patients for the management of vascular headaches (e.g., migraine). Efficacy for prophylaxis of migraine not established in randomized controlled studies, but some experts consider the drug to be effective based on consensus and clinical experience.

• Generic Name: ruxolitinib
• Dosage Forms: n.a.
• Other Brand Names: Jakafi

Treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis (designated an orphan drug by FDA for this use).